Cibc World Market Inc. Buys 10,658 Shares of IQVIA Holdings Inc. $IQV

Cibc World Market Inc. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 50.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,795 shares of the medical research company’s stock after buying an additional 10,658 shares during the period. Cibc World Market Inc.’s holdings in IQVIA were worth $6,039,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. OPTIMAS CAPITAL Ltd bought a new position in shares of IQVIA during the 3rd quarter valued at approximately $4,008,000. Amundi boosted its position in shares of IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after purchasing an additional 405,250 shares during the period. Diversified Trust Co increased its stake in shares of IQVIA by 57.2% in the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after purchasing an additional 15,487 shares in the last quarter. Nichols & Pratt Advisers LLP MA raised its position in shares of IQVIA by 8.6% during the 3rd quarter. Nichols & Pratt Advisers LLP MA now owns 122,603 shares of the medical research company’s stock valued at $23,287,000 after purchasing an additional 9,684 shares during the period. Finally, Act Two Investors LLC bought a new position in IQVIA in the 2nd quarter worth $26,528,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on IQV shares. JPMorgan Chase & Co. decreased their price target on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Evercore reissued an “outperform” rating and issued a $225.00 target price on shares of IQVIA in a report on Thursday, February 5th. Finally, Jefferies Financial Group cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $238.20.

IQVIA Trading Down 1.3%

Shares of IQV opened at $166.70 on Friday. The stock has a market capitalization of $28.39 billion, a PE ratio of 21.21, a P/E/G ratio of 1.61 and a beta of 1.37. The company’s fifty day moving average is $223.12 and its 200 day moving average is $209.07. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same quarter last year, the business earned $3.12 earnings per share. IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.